dysmenorrhea%20-%20primary
DYSMENORRHEA - PRIMARY
Primary dysmenorrhea is a painful menstruation without demonstrable pelvic disease.
Symptoms include intermittent painful spasms, crampy labor-like pain localized over the lower abdomen and the suprapubic area which may radiate to the lower back or inner thighs.
The pain may also be described as a dull ache or as a stabbing pain.
Accompanying symptoms include nausea and vomiting, diarrhea, headaches, lightheadedness, fatigue, fever, muscle cramps, nervousness and fainting.

Dysmenorrhea%20-%20primary Patient Education

Patient Education

Patient (and Parents) Education

  • Explain to the patient the nature of her dysmenorrhea and give her a chance to ask questions regarding her anatomy
  • Provide reassurance that dysmenorrhea is a treatable condition and explain the treatment options
  • Motivate patient to adopt healthy lifestyle changes (eg stop smoking, exercise regularly, adopt a low-fat vegetarian diet, do relaxation techniques)
    • Explain that these modifications may decrease painful periods
  • Counsel patients on their treatments and compliance
    • Educate patients about the side effects of each treatment so they may report if there is any appearance of undesirable side effects
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
05 Feb 2021

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.

Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Roshini Claire Anthony, 6 days ago

Critical or severe COVID-19 disease could raise the risk of negative perinatal outcomes in pregnant women, according to an observational study from the US.

Stephen Padilla, 22 Feb 2021
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.